CALIFORNIA HEART CENTER FOUNDATION: Form 990, tax year 2013
View the entire original 990 at ProPublica ↗
- Organization
- CALIFORNIA HEART CENTER FOUNDATION (EIN 95-4772979)
- Tax period
- 2013-01-01 to 2013-12-31
- Filed
- 2014-11-17
- IRS object ID
- 201413219349305181
- Schema version
- 2013v3.0
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2014-11-17T12:27:12-06:00 | ReturnTs |
| Tax Period End | 2013-12-31 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 346565596 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | ERNST & YOUNG US LLP | BusinessNameLine1 |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 18111 VON KARMAN AVENUE SUITE 1000 | AddressLine1 |
| City | IRVINE | City |
| State | CA | State |
| ZIP Code | 92612 | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2013-01-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 954772979 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | CALIFORNIA HEART CENTER FOUNDATION | BusinessNameLine1 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | CALI | BusinessNameControlTxt |
| Phone | 3102488327 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 8536 WILSHIRE BOULEVARD 3RD FLOOR | AddressLine1 |
| City | BEVERLY HILLS | City |
| State | CA | State |
| ZIP Code | 90211 | ZIPCode |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | THOMAS D GORDON | PersonNm |
| Person Title | CFO | PersonTitleTxt |
| Phone | 3102488327 | PhoneNum |
| Signature | 2014-11-17 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | KARA ADAMS | PreparerPersonNm |
| PTIN | P00023315 | PTIN |
| Phone | 9497942300 | PhoneNum |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2013 | TaxYr |
| Build TS | 2015-11-30 17:44:51Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | ERIC N MARTON | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 8536 WILSHIRE BOULEVARD 3RD FLOOR | AddressLine1 |
| City | BEVERLY HILLS | City |
| State | CA | State |
| ZIP Code | 90211 | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $1,446,748 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.CALHEART.ORG | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 2000 | FormationYr |
| Legal Domicile State | CA | LegalDomicileStateCd |
| Activity Or Mission | PROMOTE & DEVELOP EDUCATIONAL & SCIENTIFIC RESEARCH TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE. | ActivityOrMissionDesc |
| Voting Members Governing Body | 14 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 9 | VotingMembersIndependentCnt |
| Total Employee | 0 | TotalEmployeeCnt |
| Total Volunteers | 12 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $1,445,229 | PYContributionsGrantsAmt |
| CY Contributions Grants | $1,357,431 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $60,983 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $79,070 | CYProgramServiceRevenueAmt |
| PY Investment Income | -$232,193 | PYInvestmentIncomeAmt |
| CY Investment Income | $10,247 | CYInvestmentIncomeAmt |
| PY Other Revenue | $0 | PYOtherRevenueAmt |
| CY Other Revenue | $0 | CYOtherRevenueAmt |
| PY Total Revenue | $1,274,019 | PYTotalRevenueAmt |
| CY Total Revenue | $1,446,748 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $7,000 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $500 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $1,256,527 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $1,299,621 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $0 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $0 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $444,383 | PYOtherExpensesAmt |
| CY Other Expenses | $393,391 | CYOtherExpensesAmt |
| PY Total Expenses | $1,707,910 | PYTotalExpensesAmt |
| CY Total Expenses | $1,693,512 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | -$433,891 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | -$246,764 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $568,742 | TotalAssetsBOYAmt |
| Total Assets EOY | $364,788 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $99,768 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $122,813 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $468,974 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $241,975 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | THE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES. | MissionDesc |
| Significant New Program Srvc | 0 | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $1,358,727 | ExpenseAmt |
| Grant | $500 | GrantAmt |
| Revenue | $79,070 | RevenueAmt |
| Desc | THE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES. OUR EFFORTS INCLUDE THE PURSUIT OF COLLABORATIVE RESEARCH PROJECTS WHICH PROMOTE A DEEPER UNDERSTANDING OF DISEASE PROGRESSION AND TEST THE EFFICACY OF NEW STRATEGIES FOR DIAGNOSIS AND TREATMENT. AREAS OF RESEARCH CURRENTLY BEING PURSUED INCLUDE NON-INVASIVE METHODS TO DETECT ORGAN REJECTION, NOVEL IMMUNOSUPPRESSIVE AGENTS, IMMUNE MONITORING STRATEGIES, LONG-TERM COMPLICATIONS SUCH AS CARDIAC ALLOGRAFT VASCULOPATHY, (CONTINUED ON SCHEDULE O)(CONTINUATION FROM FORM 990, PAGE 2)NOVEL METHODS FOR ORGAN PROCUREMENT AND PRESERVATION, NEW MECHANICAL CIRCULATORY SUPPORT DEVICES AND PULMONARY HYPERTENSION. THE ORGANIZATION ALSO SUPPORTS IMPORTANT SCIENTIFIC SYMPOSIA, WHICH ALLOW FOR THE EXCHANGE OF IDEAS AMONG LEADERS IN THE FIELD AND PROVIDE A FORUM FOR EXPERTS TO SHARE THEIR EXPERIENCE AND KNOWLEDGE WITH OTHER PRACTITIONERS. THE ORGANIZATION RESOURCES ARE ALSO LEVERAGED TO SUPPORT A SUMMER RESEARCH INTERNSHIP PROGRAM FOR UNDERGRADUATE STUDENTS WITH AN INTEREST IN MEDICINE AND/OR ACADEMIC RESEARCH. FOLLOWING IS A SUMMARY OF PROJECTS AND PROGRAMS IMPLEMENTED IN 2013:SCIENTIFIC FORUMS AND EDUCATIONAL ACTIVITIES:* "FORUM ON U.S. HEART ALLOCATION POLICY"(DALLAS): THE FORUM ON U.S. HEART ALLOCATION POLICY TOOK PLACE IN DALLAS, TEXAS ON NOVEMBER 15TH, 2013. THIS PROGRAM PROVIDED AN OVERVIEW OF THE EVOLUTION OF HEART ALLOCATION POLICY IN THE UNITED STATES AND CURRENT ISSUES IN THE PRACTICAL APPLICATION OF THIS POLICY. THE MEETING ALLOWED FOR A DISCUSSION OF ETHICAL CONSIDERATIONS AND FOR MULTIPLE PERSPECTIVES ON POTENTIAL REVISIONS AND WAS IMPLEMENTED IN COLLABORATION WITH THE UNITED NETWORK FOR ORGAN SHARING, THE AMERICAN SOCIETY OF TRANSPLANTATION AND THE AMERICAN SOCIETY OF THORACIC SURGEONS. PARTICIPANTS, REPRESENTING PROGRAMS FROM ACROSS THE UNITED STATES, WERE ALSO ASKED TO COMPLETE A PRE MEETING SURVEY OF THEIR CURRENT EXPERIENCE, INCLUDING AVERAGE WAIT TIMES AT THEIR CENTER, USE OF MCS AS A BRIDGE TO TRANSPLANT, DEATHS ON THE WAITING LIST, ETC. TO HELP PROVIDE AN EVIDENCE BASIS FOR ANY RECOMMENDATIONS. * "EXPERTS IN MCS THERAPY: CURRENT STATE OF THE ART" (LOS ANGELES): IN COLLABORATION WITH THE CEDARS-SINAI OFFICE OF CONTINUING MEDICAL EDUCATION, WE DEVELOPED A ONE-DAY SYMPOSIUM WITH AN IN-DEPTH FOCUS ON MECHANICAL CIRCULATORY SUPPORT DEVICES, AN EMERGING AREA IN THE TREATMENT OF PATIENTS WITH HEART FAILURE. FEATURING A TRULY DISTINGUISHED FACULTY OF EXPERT SPEAKERS FROM ACROSS THE UNITED STATES, THE PROGRAM DREW OVER 225 PHYSICIANS AND ALLIED HEALTH MEMBERS FOR DIDACTIC PRESENTATIONS, CASE STUDY PRESENTATIONS, AND EXPERT PANEL DISCUSSIONS. THE HIGHLIGHT OF THE EVENT WAS THE OPPORTUNITY TO MEET WITH ACTUAL MCS PATIENTS, INCLUDING A PATIENT WITH A TOTAL ARTIFICIAL HEART. THE SYMPOSIUM WAS HELD ON SATURDAY, NOVEMBER 2ND, 2013 AT THE CENTURY PLAZA HOTEL. * "PRIMARY GRAFT DYSFUNCTION: AN INTERNATIONAL CONSENSUS CONFERENCE": THIS CONSENSUS CONFERENCE ORGANIZED AND CHAIRED BY DR JON KOBASHIGAWA OCCURRED ON TUESDAY, APRIL 23RD, 2013 IN MONTREAL, CANADA. THE PARTICIPATION OF 81 LEADING EXPERTS FROM AROUND THE WORLD ADDRESSED THE LACK OF A STANDARD DEFINITION OF PRIMARY GRAFT DYSFUNCTION (PGD), FACILITATED THE DEVELOPMENT OF DIAGNOSTIC CRITERIA AND A SEVERITY SCALE FOR PGD, DESCRIBED RISK FACTORS FOR PGD AND CREATED A PLATFORM FOR FURTHER RESEARCH TO EVALUATE THE EFFICACY OF TREATMENT OPTIONS AND PREVENTION STRATEGIES. DESIGNED AS A COLLABORATIVE PROGRAM WITH THE INTERNATIONAL SOCIETY OF HEART & LUNG TRANSPLANTATION, RESULTS OF THE CONFERENCE WERE PRESENTED ON SATURDAY, APRIL 27TH, 2013 IN THE CLOSING PLENARY SESSION OF THE ISHLT ANNUAL MEETING AND SCIENTIFIC SESSIONS. A WHITE PAPER PUBLICATION FROM THE CONFERENCE IS CURRENTLY IN DEVELOPMENT.* "SUCCESS WITH FAILURE: AN ADVANCED HEART DISEASE SYMPOSIUM": THIS ONE-DAY SYMPOSIUM WAS HELD ON THURSDAY, MARCH 7TH, 2013 AT THE UNIVERSAL HILTON IN LOS ANGELES AND FEATURED BOTH PLENARY AND CONCURRENT SESSIONS ON TOPICS RELATED TO HEART FAILURE, HEART TRANSPLANTATION AND MECHANICAL CIRCULATORY SUPPORT, INCLUDING PALLIATIVE CARE, SURGICAL OPTIONS, ETHICS, STEM CELL THERAPY, IMMUNE MONITORING AND PHARMACOLOGICAL MANAGEMENT. ATTENDED BY 257 PARTICIPANTS, INCLUDING PHYSICIANS AND ALLIED HEALTH, THE PROGRAM RECEIVED HIGHLY POSITIVE REVIEWS. * SUMMER RESEARCH INTERNSHIPS: UNDER THE SUPERVISION AND MENTORSHIP OF DR JON KOBASHIGAWA, SUMMER HEART TRANSPLANT RESEARCH INTERNSHIPS HAVE BEEN OFFERED TO SEVEN STUDENTS FOR THE SUMMER OF 2013. THESE INTERNSHIPS PROVIDE STUDENTS AT ALL LEVELS OF TRAINING AN OPPORTUNITY TO LEARN THE CLINICAL RESEARCH PROCESS, INCLUDING MEDICAL LITERATURE REVIEW, STUDY DESIGN, CHART REVIEW/DATA COLLECTION, DATA ANALYSIS, AND ABSTRACT DEVELOPMENT AND SUBMISSION. COMPLETED ABSTRACTS WILL BE SUBMITTED TO THE AMERICAN FEDERATION OF MEDICAL RESEARCH, A FORUM FOR JUNIOR INVESTIGATORS. SUMMER INTERNS FOR 2013 INCLUDE THREE FIRST-YEAR MEDICAL STUDENTS FROM MICHIGAN STATE SCHOOL OF MEDICINE, CHICAGO MEDICAL SCHOOL, AND NEW JERSEY MEDICAL SCHOOL, AND UNDERGRADUATE STUDENTS FORM UCLA AND LOYOLA MARYMOUNT UNIVERSITY.* HEART TRANSPLANT PRECEPTORSHIPS: THROUGHOUT THE YEAR, WE RECEIVE REQUESTS TO PROVIDE EXTENDED OBSERVATIONAL TRAINING OPPORTUNITIES TO PHYSICIANS AND ADVANCE PRACTICE NURSES FROM VARIOUS INSTITUTIONS WITH AN INTEREST IN THE MANAGEMENT OF HEART TRANSPLANT AND MECHANICAL ASSIST DEVICE PATIENTS. IN THE LAST YEAR, WE HOSTED VISITING PHYSICIANS AND NURSES FROM:NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, JAPANSEOUL UNIVERSITY, KOREAMEDSTAR WASHINGTON MEDICAL CENTER (GEORGETOWN UNIVERSITY)BAKERSFIELD MEMORIAL HOSPITALSIMI VALLEY MEDICAL CENTERTOKYO UNIVERSITY MEDICAL CENTERSTANFORD UNIVERSITY MEDICAL CENTERTHE ALFRED HOSPITAL, MELBOURNE, AUSTRALIAUNIVERSITY OF SANTIAGO DE COMPOSTELA, SPAINPUNTA PACIFICA HOSPITAL, PANAMAPRECEPTORSHIPS GENERALLY TAKE PLACE OVER THE COURSE OF TWO WEEKS AND UP TO THREE MONTHS, DEPENDING ON THE FOCUS OF THE TRAINING. TRAINING INCLUDES PARTICIPATION IN IN-HOSPITAL ROUNDS, OUT-PATIENT CLINIC VISITS, SURGERY/DEVICE IMPLANTATION OBSERVATIONS, DIDACTIC LECTURES, CASE STUDIES, JOURNAL CLUBS AND RESEARCH MEETINGS.CLINICAL RESEARCH:STUDY TITLE: CLINICAL TRIALS IN ORGAN TRANSPLANTATION (CTOT-11): NOVEL THERAPIES TO IMPROVE RENAL AND CARDIAC ALLOGRAFT OUTCOMESSPONSOR: NIH/BRIGHAM AND WOMEN'S HOSPITALPROJECT SUMMARY: TRANSPLANTATION IS THE IDEAL THERAPY FOR END STAGE HEART AND END STAGE KIDNEY FAILURE, BUT ALLOGRAFT SURVIVAL AND FUNCTION REMAIN SUBOPTIMAL. THE OVERRIDING CLINICAL HYPOTHESIS IS THAT SPECIFICALLY DESIGNED THERAPIES GUIDED BY RATIONALLY CHOSEN NONINVASIVE IMMUNE MONITORING WILL IMPROVE OUTCOMES IN HEART AND KIDNEY TRANSPLANT RECIPIENTS. THE STUDY INVOLVES IDENTIFYING HEART TRANSPLANT CANDIDATES AT HIGH RISK FOR ANTIBODY MEDIATED INJURY (HIGH PRA) AND PERFORMING A PILOT STUDY TO DETERMINE THE SAFETY AND EFFICACY OF DESENSITIZATION USING A COMBINATION OF B CELL DEPLETION (RITUXIMAB) AND IVIG PLASMAPHERESIS. THE STUDY WILL TEST THE HYPOTHESIS THAT DESENSITIZATION WILL LOWER PRA, DIMINISH THE WAITING TIME TO HEART TRANSPLANTATION AND RESULT IN ACCEPTABLE 1 YEAR GRAFT SURVIVAL AND FUNCTION. ASSOCIATED MECHANISTIC STUDIES WILL DETERMINE HOW THE DESENSITIZATION PROTOCOL IMPACTS PREFORMED ALLOREACTIVE T AND B CELL IMMUNITY AND WILL TEST THE HYPOTHESIS THAT RESIDUAL B AND T CELL IMMUNE MEMORY WITH REACTIVITY TO DONOR ANTIGENS MEDIATES POST-TRANSPLANT ALLOGRAFT INJURY. STUDY TITLE: ACE INHIBITION AND CARDIAC ALLOGRAFT VASCULOPATHYSPONSOR: NIH/STANFORD UNIVERSITYPROJECT SUMMARY: THE PURPOSE OF THIS STUDY IS TO INVESTIGATE THE EFFECT OF THE ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACE I), RAMIPRIL, AN ANTIHYPERTENSIVE AGENT, ON THE DEVELOPMENT OF CARDIAC ALLOGRAFT VASCULOPATHY (CAV) IN CARDIAC TRANSPLANT RECIPIENTS IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. CARDIAC ALLOGRAFT VASCULOPATHY (CAV) IS A LEADING CAUSE OF MORBIDITY AND MORTALITY AFTER HEART TRANSPLANT. DESPITE ADVANCES IN PROPHYLAXIS AGAINST REJECTION AND INFECTION, AS WELL AS IMPROVED CONTROL OF TRADITIONAL ATHEROSCLEROTIC RISK FACTORS, SIGNIFICANT DEVELOPMENT OF ATHEROSCLEROTIC PLAQUE AND DETRIMENTAL VASCULAR REMODELING OCCUR EARLY AFTER ORTHOTOPIC HEART TRANSPLANTATION (OHT). THE INVESTIGATORS HOPE TO DETERMINE WHETHER ACE I THERAPY WITH RAMIPRIL EARLY AFTER OHT IMPACTS THE DEVELOPMENT OF CAV, AND LEARN IF THE USE OF ACE I INCREASES THE NUMBER OF CIRCULATING ENDOTHELIAL PROGENITOR CELLS (EPC) RESULTING IN IMPROVED ENDOTHELIAL FUNCTION AND LESS ATHEROSCLEROSIS. THE PRIMARY OBJECTIVE IS TO INVESTIGATE THE EFFECT OF ACE I ON THE DEVELOPMENT OF CAV IN CARDIAC TRANSPLANT RECIPIENTS IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. | Desc |
| Total Program Service Expenses | $1,358,727 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (1) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (1) | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Lobbying Activities | 0 | LobbyingActivitiesInd |
| Subject To Proxy Tax | 0 | SubjectToProxyTaxInd |
| Donor Advised Fund | 0 | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | 0 | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Temp Or Permanent Endowments | 0 | TempOrPermanentEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | 0 | ReportOtherAssetsInd |
| Report Other Liabilities | 0 | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | 0 | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | 0 | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | 0 | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | 0 | ForeignOfficeInd |
| Foreign Activities | 0 | ForeignActivitiesInd |
| More Than5000 K To Org | 0 | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividualsInd |
| Professional Fundraising | 0 | ProfessionalFundraisingInd |
| Fundraising Activities | 0 | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | 0 | GrantsToOrganizationsInd |
| Grants To Individuals | 0 | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | 0 | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | 0 | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | 0 | PYExcessBenefitTransInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | 0 | BusinessRlnWithFamMemInd |
| Business Rln With Officer Ent | 0 | BusinessRlnWithOfficerEntInd |
| Deductible Non Cash Contri | 0 | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | 0 | DisregardedEntityInd |
| Related Entity | Yes (1) | RelatedEntityInd |
| Related Organization Ctrl Ent | Yes (1) | RelatedOrganizationCtrlEntInd |
| Transaction With Control Ent | 0 | TransactionWithControlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | 0 | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| IRP Document | 4 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (1) | BackupWthldComplianceInd |
| Employee | 0 | EmployeeCnt |
| Unrelated Bus Incm Over Limit | 0 | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | 0 | ForeignFinancialAccountInd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | 0 | QuidProQuoContributionsInd |
| Form8282 Property Disposed Of | 0 | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | 0 | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | 0 | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 14 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 9 | IndependentVotingMemberCnt |
| Family Or Business Rln | Yes (1) | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | 0 | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | Yes (1) | MembersOrStockholdersInd |
| Election Of Board Members | Yes (1) | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | Yes (1) | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | 0 | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (1) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (1) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | 0 | WhistleblowerPolicyInd |
| Document Retention Policy | 0 | DocumentRetentionPolicyInd |
| Compensation Process CEO | 0 | CompensationProcessCEOInd |
| Compensation Process Other | Yes (1) | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | CA | StatesWhereCopyOfReturnIsFldCd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | ERIC MARTON | BusinessNameLine1 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 3102488327 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 8536 WILSHIRE BOULEVARD 3RD FLOOR | AddressLine1 |
| City | BEVERLY HILLS | City |
| State | CA | State |
| ZIP Code | 90211 | ZIPCode |
Form990 Part VII Section A Form990PartVIISectionAGrp (19 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | OfficerOfficerInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt |
|---|---|---|---|---|---|---|---|
| JON KOBASHIGAWA MD | |||||||
| CHIEF MEDICAL DIRECTOR | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 |
| KEENAN BEHRLE | |||||||
| CHAIRPERSON | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 |
| JAMES HAMILTON | |||||||
| SECRETARY | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 |
| KAY DILLARD | |||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |
| THOMAS D GORDON | |||||||
| CFO | 1.00 | 65.00 | Yes (X) | Yes (X) | $0 | $1,171,581 | $207,121 |
| RUSSELL FAUCETT | |||||||
| DIRECTOR - PART YEAR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |
| IRENE FURLONG | |||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |
| MICHELE HAMILTON MD | |||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |
| RICHARD B JACOBS | |||||||
| DIRECTOR | 1.00 | 61.00 | Yes (X) | $0 | $1,697,300 | $166,214 | |
| E ERIC JOHNSON | |||||||
| DIRECTOR - PART YEAR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |
| JOSEPH O LAMPE | |||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |
| EDUARDO MARBAN MD | |||||||
| DIRECTOR | 1.00 | 60.00 | Yes (X) | $0 | $1,918,262 | $226,336 | |
| LAURENCE MARTON MD | |||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |
| ARTHUR J OCHOA | |||||||
| DIRECTOR | 1.00 | 65.00 | Yes (X) | $0 | $707,111 | $60,851 | |
| WILLIAM OUCHI PHD | |||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |
| EDWARD PRUNCHUNAS | |||||||
| DIRECTOR | 1.00 | 65.00 | Yes (X) | $0 | $1,263,700 | $307,721 | |
| LAWRENCE SOUZA PHD | |||||||
| DIRECTOR - PART YEAR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |
| ERIC N MARTON | |||||||
| PRESIDENT | 30.00 | 30.00 | Yes (X) | $0 | $349,178 | $31,879 | |
| CHRISTINE SUMBI | |||||||
| VICE-PRESIDENT | 40.00 | 0.00 | Yes (X) | $0 | $135,568 | $17,879 | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $0 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $7,242,700 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $1,018,001 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 0 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | 0 | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
| Cntrct Rcvd Greater Than100 K | 0 | CntrctRcvdGreaterThan100KCnt |
| Related Organizations | $1,348,784 | RelatedOrganizationsAmt |
| All Other Contributions | $8,647 | AllOtherContributionsAmt |
| Total Contributions | $1,357,431 | TotalContributionsAmt |
Program Service Revenue ProgramServiceRevenueGrp (2 entries)
| DescDesc | BusinessBusinessCd | Total Revenue ColumnTotalRevenueColumnAmt | Related Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt |
|---|---|---|---|
| EDUCATIONAL PROGRAMS | 611430 | $68,012 | $68,012 |
| CULTURAL PROGRAMS | 611710 | $11,058 | $11,058 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $79,070 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $8,138 | TotalRevenueColumnAmt |
| Exclusion | $8,138 | ExclusionAmt |
Gross Amount Sales Assets GrossAmountSalesAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $2,109 | SecuritiesAmt |
Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $0 | SecuritiesAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $2,109 | SecuritiesAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $2,109 | TotalRevenueColumnAmt |
| Exclusion | $2,109 | ExclusionAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $1,446,748 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $79,070 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $10,247 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $500 | TotalAmt |
| Program Services | $500 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $295,289 | TotalAmt |
| Management And General | $295,289 | ManagementAndGeneralAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $745,552 | TotalAmt |
| Program Services | $745,552 | ProgramServicesAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $46,165 | TotalAmt |
| Program Services | $46,165 | ProgramServicesAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $134,597 | TotalAmt |
| Program Services | $134,597 | ProgramServicesAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $78,018 | TotalAmt |
| Program Services | $78,018 | ProgramServicesAmt |
Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,500 | TotalAmt |
| Management And General | $2,500 | ManagementAndGeneralAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $25,709 | TotalAmt |
| Program Services | $18,253 | ProgramServicesAmt |
| Management And General | $7,456 | ManagementAndGeneralAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $25,879 | TotalAmt |
| Program Services | $23,291 | ProgramServicesAmt |
| Management And General | $2,588 | ManagementAndGeneralAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $13,408 | TotalAmt |
| Program Services | $6,704 | ProgramServicesAmt |
| Management And General | $6,704 | ManagementAndGeneralAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $49,397 | TotalAmt |
| Program Services | $49,397 | ProgramServicesAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $19,493 | TotalAmt |
| Program Services | $19,493 | ProgramServicesAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $229,722 | TotalAmt |
| Program Services | $218,236 | ProgramServicesAmt |
| Management And General | $11,486 | ManagementAndGeneralAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $12,832 | TotalAmt |
| Program Services | $12,832 | ProgramServicesAmt |
Other Expenses OtherExpensesGrp (4 entries)
| DescDesc | TotalTotalAmt | Management And GeneralManagementAndGeneralAmt | Program ServicesProgramServicesAmt |
|---|---|---|---|
| BANK CHARGES | $4,128 | $4,128 | |
| DUES & SUBSCRIPTIONS | $3,868 | $3,868 | |
| CREDIT CARD FEES | $2,005 | $2,005 | |
| OTHER PURCHASED SERVICE | $2,000 | $2,000 |
All Other Expenses AllOtherExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,450 | TotalAmt |
| Program Services | $1,821 | ProgramServicesAmt |
| Management And General | $629 | ManagementAndGeneralAmt |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,693,512 | TotalAmt |
| Program Services | $1,358,727 | ProgramServicesAmt |
| Management And General | $334,785 | ManagementAndGeneralAmt |
| Fundraising | $0 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $110,187 | BOYAmt |
| EOY | $95,134 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $15,650 | BOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $20,435 | BOYAmt |
| EOY | $3,085 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $107,678 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $87,386 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $18,879 | BOYAmt |
| EOY | $20,292 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $403,591 | BOYAmt |
| EOY | $246,277 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $568,742 | BOYAmt |
| EOY | $364,788 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $99,768 | BOYAmt |
| EOY | $122,813 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $99,768 | BOYAmt |
| EOY | $122,813 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows SFAS117 | Yes (X) | OrganizationFollowsSFAS117Ind |
Unrestricted Net Assets UnrestrictedNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $468,974 | BOYAmt |
| EOY | $241,975 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $468,974 | BOYAmt |
| EOY | $241,975 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $568,742 | BOYAmt |
| EOY | $364,788 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Reconcilation Revenue Expnss | -$246,764 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | $19,765 | NetUnrlzdGainsLossesInvstAmt |
| Other Changes In Net Assets | $0 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | 0 | FSAuditedInd |
| Federal Grant Audit Required | 0 | FederalGrantAuditRequiredInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $1,202,798 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $2,355,777 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $1,280,861 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $1,445,229 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $1,357,431 | CurrentTaxYearAmt |
| Total | $7,642,096 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $1,202,798 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $2,355,777 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $1,280,861 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $1,445,229 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $1,357,431 | CurrentTaxYearAmt |
| Total | $7,642,096 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $1,511,981 | SubstantialContributorsTotAmt |
| Public Support Total170 | $6,130,115 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $7,427 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $12,029 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $18,834 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $12,225 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $8,138 | CurrentTaxYearAmt |
| Total | $58,653 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $7,700,749 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $272,941 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.79600 | PublicSupportCY170Pct |
| Public Support PY170 | 0.63800 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule D IRS990ScheduleD
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $70,594 | OtherCostOrOtherBasisAmt |
| Depreciation | $58,249 | DepreciationAmt |
| Book Value | $12,345 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $37,084 | OtherCostOrOtherBasisAmt |
| Depreciation | $29,137 | DepreciationAmt |
| Book Value | $7,947 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $20,292 | TotalBookValueLandBuildingsAmt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Severance Payment | 0 | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | Yes (1) | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | 0 | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | 0 | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | 0 | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | 0 | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | 0 | AnyNonFixedPaymentsInd |
| Initial Contract Exception | 0 | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (7 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| THOMAS D GORDON | ||||||||||||||
| CFO | $0 | $507,587 | $0 | $251,910 | $0 | $412,084 | $0 | $175,722 | $0 | $31,399 | $0 | $1,378,702 | $0 | $0 |
| RICHARD B JACOBS | ||||||||||||||
| DIRECTOR | $0 | $550,082 | $0 | $267,319 | $0 | $879,899 | $0 | $148,210 | $0 | $18,004 | $0 | $1,863,514 | $0 | $0 |
| EDUARDO MARBAN MD | ||||||||||||||
| DIRECTOR | $0 | $1,272,722 | $0 | $267,590 | $0 | $377,950 | $0 | $186,995 | $0 | $39,341 | $0 | $2,144,598 | $0 | $0 |
| ARTHUR J OCHOA | ||||||||||||||
| DIRECTOR | $0 | $451,691 | $0 | $214,649 | $0 | $40,771 | $0 | $21,675 | $0 | $39,176 | $0 | $767,962 | $0 | $0 |
| EDWARD PRUNCHUNAS | ||||||||||||||
| DIRECTOR | $0 | $672,181 | $0 | $311,157 | $0 | $280,362 | $0 | $277,661 | $0 | $30,060 | $0 | $1,571,421 | $0 | $0 |
| ERIC N MARTON | ||||||||||||||
| PRESIDENT | $0 | $306,564 | $0 | $25,600 | $0 | $17,014 | $0 | $7,650 | $0 | $24,229 | $0 | $381,057 | $0 | $0 |
| CHRISTINE SUMBI | ||||||||||||||
| VICE-PRESIDENT | $0 | $129,612 | $0 | $5,700 | $0 | $256 | $0 | $8,077 | $0 | $9,802 | $0 | $153,447 | $0 | $0 |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 3 | THE PRESIDENT IS COMPENSATED BY A RELATED ORGANIZATION. PLEASE SEE SCHEDULE O NARRATIVE FOR PART VI, LINE 15. |
| PART I, LINE 4B | THE PLAN IS A SUPPLEMENTAL RETIREMENT ALLOWANCE THAT IS PAYABLE DIRECTLY TO THE PARTICIPANTS EACH QUARTER. THE BENEFIT FORMULA FOR THIS PLAN HAS ANNUAL CONTRIBUTIONS THAT ARE EITHER A PERCENTAGE OF SALARY, OR ARE DESIGNED TO FUND A PERCENTAGE OF THE ESTIMATED FINAL 5-YEAR AVERAGE SALARY. IN ADDITION, TWO INDIVIDUALS HAVE A RETENTION INCENTIVE WHICH HAD A CLIFF VESTING DATE IN 2013. THE FOLLOWING OFFICERS, DIRECTORS, AND KEY EMPLOYEES RECEIVED PAYMENTS DURING THE YEAR ENDED DECEMBER 31, 2013. THOMAS D. GORDON 383,951 RICHARD B. JACOBS 829,174 EDUARDO MARBAN, MD 188,640 ERIC N. MARTON 14,393 ARTHUR J. OCHOA 36,941 EDWARD PRUNCHUNAS 216,642 |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (12 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART III, LINE 4A | (CONTINUED) STUDY TITLE: LONG TERM OUTCOME FOLLOW-UP OF THE RAD001 B253 STUDY, EVEROLIMUS FOR THE PREVENTION OF ALLOGRAFT REJECTION AND VASCULOPATHY IN CARDIAC-TRANSPLANT RECIPIENTS SPONSOR: NOVARTIS PROJECT SUMMARY: SURVIVAL FOR TRANSPLANT RECIPIENTS IS STILL LIMITED BY CARDIAC ALLOGRAFT VASCULOPATHY (CAV), INFECTIOUS COMPLICATIONS, MALIGNANCY, AND REJECTION. IN THE LANDMARK HEART TRANSPLANT STUDY RAD001 B253 WITH ALL GROUPS GIVEN CYCLOSPORINE, BOTH DOSES OF EVEROLIMUS (1.5 AND 3 MG/DAY) WERE SUPERIOR TO AZATHIOPRINE FOR EFFICACY FAILURE AT 6, 12, AND 24 MONTHS POST TRANSPLANTATION. THIS FINDING WAS PRIMARILY DUE TO A REDUCTION IN THE INCIDENCE OF ACUTE REJECTION (ISHLT GREATER THAN OR EQUAL TO GRADE 3A) IN THE EVEROLIMUS GROUPS. THE RAD B253 STUDY ALSO CONFIRMED THAT EVEROLIMUS APPEARED TO BE MORE BENEFICIAL THAN AZATHIOPRINE IN REDUCING THE SEVERITY AND INCIDENCE OF CAV AT 1-YEAR POST TRANSPLANTATION. HOWEVER, THE LONG TERM BENEFIT OF EVEROLIMUS IN HEART TRANSPLANT PATIENTS HAS YET TO BE ESTABLISHED AND THUS, A STUDY EVALUATING LONG-TERM OUTCOMES IS WARRANTED. THE PURPOSE OF THIS STUDY IS TO COMPARE THE 10-YEAR OUTCOMES OF CARDIAC TRANSPLANT PATIENTS ORIGINALLY RANDOMIZED TO EVEROLIMUS 1.5MG, EVEROLIMUS 3.0MG AND AZATHIOPRINE GROUPS FROM THE MULTI-CENTER RAD001 B253 STUDY. THESE OUTCOMES INCLUDE SURVIVAL, CARDIAC ALLOGRAFT VASCULOPATHY (CAV) BY ANGIOGRAPHY, AND NON-FATAL MAJOR ADVERSE CARDIAC EVENTS. THIS IS AN INVESTIGATOR-INITIATED STUDY WHERE CEDARS-SINAI IS SERVING AS THE COORDINATING SITE, GATHERING LONG-TERM FOLLOW UP DATA ON PATIENTS FROM THE ORIGINAL STUDY. STUDY TITLE: ADVANCED HEART DISEASE REGISTRY STUDY SPONSOR: INTERNAL PROJECT SUMMARY: HEART FAILURE IS A COMPLEX PROGRESSIVE MULTISYSTEM DISEASE STATE AFFECTING OVER 5 MILLION AMERICANS WITH SIGNIFICANT MORBIDITY AND MORTALITY. THERE HAS BEEN SIGNIFICANT IMPROVEMENT IN THE SURVIVAL OF PATIENTS DIAGNOSED WITH HF OVER THE RECENT YEARS WITH MUCH BEING OWED TO MEDICAL THERAPY ADVANCES AND A DEEPER KNOWLEDGE OF THE NEURO-HORMONAL CONTRIBUTION TO THIS CONDITION. WITH A YEARLY INCIDENCE OF 500,000 NEWLY DIAGNOSED HEART FAILURE PATIENTS, HEART FAILURE CONTINUES TO BE A MAJOR PUBLIC HEALTH BURDEN, AND IS THE MOST COMMON REASON FOR HOSPITAL ADMISSION FOR PATIENTS ABOVE 65 YEARS OF AGE. DESPITE SIGNIFICANT IMPROVEMENT IN MORBIDITY AND MORTALITY OVER TIME, HEART FAILURE REMAINS A CHRONIC DISEASE CHARACTERIZED BY RECURRENT DECOMPENSATIONS AND PERSISTENT SYMPTOMS. THE PURPOSE OF THIS CLINICAL RESEARCH IS TO RETROSPECTIVELY REVIEW DATA ON PATIENTS DIAGNOSED WITH HEART FAILURE, INCLUDING THOSE WHO ARE MAINTAINED ON MEDICAL THERAPY, THOSE WHO RECEIVE A HEART TRANSPLANT AND THOSE WHO RECEIVE MECHANICAL CIRCULATORY SUPPORT. THE RESEARCH WILL ADDRESS A VARIETY OF FACTORS INCLUDING QUALITY OF LIFE, CLINICAL OUTCOMES, MEDICAL AND SURGICAL THERAPIES, COMPLIANCE, USE OF INOTROPES, GENDER DIFFERENCES, AGE DIFFERENCES, SEXUAL DYSFUNCTION, VENTRICULAR ASSIST DEVICES, OBESITY, DIET, NUTRITION, PSYCHOSOCIAL FACTORS, PATHOLOGY DATA, LAB VALUES, SPIRITUALITY COUNSELING, PALLIATIVE CARE INTERVENTIONS, REHOSPITALIZATIONS, CLINICAL INTERVENTIONS, HEMODYNAMIC CHANGES, AND THE IMPACT ON BOTH SHORT-TERM AND LONG-TERM SURVIVAL AND QUALITY OF LIFE. BY EVALUATING THE DATA OF ALL OF OUR ADVANCED HEART DISEASE PATIENTS IN ONE COMPREHENSIVE DATABASE STUDY, WE HOPE TO IMPROVE OUR UNDERSTANDING OF HEART FAILURE AS WELL AS IMPROVE THE QUALITY OF LIFE OF OUR ADVANCED HEART DISEASE PATIENTS. STUDY TITLE: HOME ECG MONITORING TO DETECT ALLOGRAFT REJECTION FOLLOWING HEART TRANSPLANTATION SPONSOR: NIH/UNIVERSITY OF CALIFORNIA, SAN FRANCISCO PROJECT SUMMARY: THE BROAD, LONG-TERM GOAL OF THIS RESEARCH IS TO APPLY NOVEL TECHNOLOGY FOR EARLY DETECTION OF DONOR ORGAN (ALLOGRAFT) REJECTION TO IMPROVE PATIENT OUTCOMES FOLLOWING HEART TRANSPLANTATION. THE SPECIFIC GOAL OF THIS INITIAL STUDY IS TO DETERMINE WHETHER DAILY MONITORING OF THE TRANSPLANT RECIPIENT'S ELECTROCARDIOGRAM (ECG) USING A SIMPLE HOME DEVICE WITH TELEPHONE TRANSMISSION TO AN ECG CORE LABORATORY WOULD PROVIDE AN EARLY SENSITIVE AND SPECIFIC BIOMARKER FOR ACUTE ALLOGRAFT REJECTION. THE SPECIFIC AIMS OF THE STUDY ARE TO: 1) DETERMINE WHETHER AN INCREASE IN THE QT INTERVAL DURING THE FIRST 6 MONTHS FOLLOWING HEART TRANSPLANT IS A SENSITIVE AND SPECIFIC BIOMARKER FOR BIOPSY-DIAGNOSED ACUTE ALLOGRAFT REJECTION; AND 2) DETERMINE THE TIMING OF INITIAL INCREASED QT INTERVAL RELATIVE TO BIOPSY-DIAGNOSED STAGES OF MILD, MODERATE, AND SEVERE ALLOGRAFT REJECTION. THE SECONDARY AIMS ARE TO: 1) DETERMINE WHETHER AN INCREASE IN THE QT INTERVAL DURING THE FIRST 6 MONTHS FOLLOWING HEART TRANSPLANT PREDICTS ALL-CAUSE OR SUDDEN CARDIAC DEATH MORTALITY WITHIN THE FIRST YEAR; AND 2) EXPLORE ADDITIONAL ECG MEASUREMENTS THAT MIGHT PREDICT ACUTE ALLOGRAFT REJECTION OR DEATH. STUDY TITLE: ENDOTHELIAL CELL REPLACEMENT BY THE HOST AFTER HEART TRANSPLANTATION AND ITS CORRELATION WITH DSA LEVEL AND ALLOGRAFT OUTCOME SPONSOR: TERASAKI FOUNDATION PROJECT SUMMARY: THE PRESENCE OF RECIPIENT DERIVED ENDOTHELIAL CELLS IN THE DONOR ORGAN IS KNOWN AS ENDOTHELIAL CHIMERISM IN TRANSPLANTED ORGANS. SINCE THE 1960S, THERE IS RISING EVIDENCE FOR CELL TRAFFIC FROM THE GRAFT INTO THE HOST AND VICE VERSA FOLLOWING SOLID ORGAN TRANSPLANTATION, AND IT IS BECOMING CLEAR THAT THESE PROCESSES INFLUENCE WHETHER AN ALLOGRAFT IS ACCEPTED OR REJECTED. THE MIGRATION OF RECIPIENT ENDOTHELIAL CELLS INTO TRANSPLANTED ORGANS IS OF SPECIAL INTEREST, AS THIS FORM OF CELL MIGRATION MAY PLAY A KEY ROLE IN ALLOGRAFT ACCEPTANCE. DESPITE THE CLEAR AND WIDELY ACCEPTED NEGATIVE CORRELATION OF DONOR-SPECIFIC ANTIBODIES AND LONG-TERM ALLOGRAFT OUTCOME IN SOLID ORGAN TRANSPLANTATION, THERE ARE STILL A NUMBER OF PATIENTS PRESENTING WITH DONOR SPECIFIC ANTIBODIES THAT DO NOT INTERFERE WITH ALLOGRAFT FUNCTION, EVEN FOR A LONG PERIOD OF TIME. WE HYPOTHESIZE, THAT IN THESE PATIENTS, ENDOTHELIAL CHIMERISM LED TO A TOLERANCE OF THE RECIPIENT IMMUNE SYSTEM TOWARDS THE FOREIGN ORGAN, THEREFORE LEADING TO STABLE ALLOGRAFT FUNCTION DESPITE THE PRESENCE OF DONOR SPECIFIC ANTIBODIES. THIS STUDY WILL TEST FOR ENDOTHELIAL CELL REPLACEMENT IN EXISTING STORED BIOPSY SAMPLES OF PATIENTS ONE YEAR POST HEART TRANSPLANTATION. OUR AIM IS THE EVALUATION OF ENDOTHELIAL CELL CHIMERISM IN CARDIAC ALLOGRAFTS, ITS CORRELATION TO DONOR SPECIFIC ANTIBODY LEVEL AND ITS IMPACT ON ALLOGRAFT OUTCOMES. THE RESULTS MAY HELP TO BETTER UNDERSTAND THE MECHANISMS OF GRAFT ACCEPTANCE AND REJECTION AND THUS MAY HELP IN THE DECISION WHETHER A PATIENT WITH DONOR SPECIFIC ANTIBODIES AFTER ORGAN TRANSPLANTATION NEEDS FURTHER THERAPY OR NOT. |
| FORM 990, PART IV, LINE 12 | THE ORGANIZATION WAS INCLUDED IN A CONSOLIDATED, INDEPENDENT AUDITED FINANCIAL STATEMENTS FOR THE FISCAL YEARS ENDED 6/30/13 AND 6/30/14 DUE TO THE FACT THAT THE TAX YEAR OF ITS TAX-EXEMPT PARENT ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, ENDS ON 6/30. THERE ARE NO AUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 12/31/13. |
| FORM 990, PART III, LINE 4A | (CONTINUED) ISCHEMIA STUDY (INTERNATIONAL STUDY OF COMPARATIVE HEALTH EFFECTIVENESS WITH MEDICAL AND INVASIVE APPROACHES) SPONSOR: NIH/NEW YORK SCHOOL OF MEDICINE PROJECT SUMMARY: CORONARY ARTERY DISEASE (CAD) IS THE LEADING CAUSE OF DEATH AND DISABILITY WORLDWIDE AND AFFECTS 17.6 MILLION AMERICANS, RESULTING IN ABOUT 450,000 DEATHS IN THE UNITED STATES ANNUALLY. GLOBALLY, 7.2 MILLION DEATHS ARE CAUSED BY CAD EACH YEAR. AN INVASIVE APPROACH TO THE EVALUATION AND TREATMENT OF CAD IS COMMON, YET EVIDENCE THAT THIS APPROACH TO MANAGEMENT FAVORABLY INFLUENCES LONG-TERM CLINICAL OUTCOMES IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE (SIHD) IS OUTDATED. OBSERVATIONAL DATA SUGGEST THAT EARLY REVASCULARIZATION IS ASSOCIATED WITH A LOWER LIKELIHOOD OF DEATH AND MYOCARDIAL INFARCTION (MI) IN PATIENTS WITH AT LEAST MODERATE ISCHEMIA ON MYOCARDIAL PERFUSION IMAGING, BUT THIS CONCEPT HAS NEVER BEEN FULLY TESTED IN A PROSPECTIVE, RANDOMIZED CLINICAL TRIAL. PREVIOUS STUDY RESULTS SUPPORT THE HYPOTHESIS THAT THE BENEFIT OF AN INVASIVE STRATEGY IN SIHD PATIENTS IS MOST LIKELY TO BE OBSERVED IN PATIENTS WITH AT LEAST MODERATE ISCHEMIA. IN CONTRAST, A NEWER, UNPUBLISHED ANALYSIS OF OUTCOMES IN THIS COHORT OF PATIENTS SHOWED NO REDUCTION IN DEATH AND MI. MODERATE OR SEVERE ISCHEMIA IS A MARKER FOR INCREASED RISK FOR DEATH, BUT NO WELL-DESIGNED CLINICAL TRIAL OF PATIENTS WITH THIS DEGREE OF ISCHEMIA HAS STUDIED WHETHER AN INVASIVE STRATEGY IMPROVES CLINICAL OUTCOMES AND QUALITY OF LIFE. GIVEN THE POTENTIAL CLINICAL BENEFIT FROM REVASCULARIZATION ON THE ONE HAND, THE SIGNIFICANT EXPENSE OF AN INVASIVE STRATEGY ON THE OTHER, THIS IS A CRITICALLY IMPORTANT ISSUE TO RESOLVE. THE RESULTS OF THE ISCHEMIA STUDY WILL HAVE PROFOUND IMPLICATIONS FOR GUIDELINES, HEALTH POLICY, AND CLINICAL PRACTICE. THIS STUDY AT CSMC PROPOSES TO ENROLL APPROXIMATELY 10 SUBJECTS WITH SIHD. SUBJECTS WILL BE CONSENTED FOLLOWING CLINICALLY-INDICATED STRESS IMAGING. IF THE IMAGES QUALIFY FOR ENROLLMENT, CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY (CCTA) WILL BE PERFORMED AND SUBJECTS WILL BE RANDOMIZED TO EITHER THE INVASIVE STRATEGY INVOLVING CATHETERIZATION AND REVASCULARIZATION OR THE OPTIMAL MEDICAL MANAGEMENT STRATEGY. BLOOD WILL ALSO BE DRAWN IN BOTH GROUPS TO ANALYZE BIOMARKERS AND ESTABLISH A GENOMICS BIOREPOSITORY. FOLLOW-UP IN RANDOMIZED SUBJECTS WILL OCCUR AT 1.5, 3, 6, AND 12 MONTHS FOLLOWING RANDOMIZATION DURING THE FIRST YEAR AND EVERY 6 MONTHS THEREAFTER, WITH CLINIC VISITS, PHONE FOLLOW-UP, AND OTHER CLINICALLY-INDICATED TESTING UNTIL THE END OF THE TRIAL. STUDY TITLE: SYNCARDIA FREEDOM DRIVER SYSTEM STUDY SPONSOR: SYNCARDIA SYSTEMS, INC. PROJECT SUMMARY: ON 15 OCTOBER 2004, THE SYNCARDIA TEMPORARY TOTAL ARTIFICIAL HEART (TAH-T) RECEIVED FDA APPROVAL (PREMARKET APPROVAL APPLICATION [PMA] #P030011) FOR IN-HOSPITAL USE AS A BRIDGE TO TRANSPLANT IN CARDIAC TRANSPLANT-ELIGIBLE CANDIDATES AT RISK OF IMMINENT DEATH FROM BIVENTRICULAR FAILURE. THE IMPLANTABLE TAH-T IS POWERED BY AN EXTERNAL PNEUMATIC DRIVER, THE CIRCULATORY SUPPORT SYSTEM (CSS) CONSOLE. BECAUSE THE SIZE AND WEIGHT OF THE CSS CONSOLE LIMIT THE MOBILITY OF TAH-T PATIENTS, SYNCARDIA DEVELOPED A SMALLER, PORTABLE EXTERNAL PNEUMATIC DRIVER, THE FREEDOM DRIVER SYSTEM, WHICH INCORPORATES SOME OF THE CSS CONSOLE OPERATING PARAMETERS TO PROVIDE THE PNEUMATIC SUPPORT REQUIRED BY THE IMPLANTED TAH-T IN CLINICALLY STABLE PATIENTS, WHILE ENHANCING THEIR MOBILITY. DESIGN VERIFICATION TEST RESULTS DEMONSTRATE THAT THE FREEDOM DRIVER OPERATES WITHIN THE SPECIFICATIONS OF THE CSS CONSOLE TO PROVIDE THE PULSATILE PNEUMATIC PRESSURES REQUIRED TO SUPPORT CLINICALLY STABLE TAH-T PATIENTS SAFELY IN AND OUT OF THE HOSPITAL. THIS CLINICAL STUDY IS INTENDED TO * CONFIRM THE DESIGN VERIFICATION TEST RESULTS THAT DEMONSTRATED THAT THE FREEDOM DRIVER IS A SUITABLE PNEUMATIC DRIVER FOR CLINICALLY STABLE TAH-T PATIENTS AND * CONFIRM THAT PATIENTS AND LAY CAREGIVERS CAN BE TRAINED TO MANAGE THE FREEDOM DRIVER SYSTEM SAFELY OUTSIDE THE HOSPITAL. STUDY TITLE: EXTERNAL FACTORS AND OUTCOMES FOR HEART TRANSPLANT RECIPIENTS: A SINGLE CENTER SURVEY STUDY SPONSOR: INTERNAL PROJECT SUMMARY: CARDIAC TRANSPLANTATION IS CURRENTLY THE PROCEDURE OF CHOICE FOR SELECTED PATIENTS WITH END-STAGE HEART DISEASE THAT IS NOT AMENABLE TO FURTHER MEDICAL INTERVENTION OR CONVENTIONAL CARDIAC PROCEDURES. WITH THE ADVENT OF MORE EFFECTIVE IMMUNOSUPPRESSIVE AGENTS, THE DEFINITION OF THE SUCCESSFULLY MANAGED HEART TRANSPLANT RECIPIENT IS EVOLVING BEYOND THE IMMEDIATE CHALLENGE OF PREVENTING ACUTE REJECTION. THE PURPOSE OF THIS SURVEY STUDY IS TO ASSESS A VARIETY OF FACTORS AND THEIR IMPACT ON BOTH SHORT-TERM AND LONG-TERM OUTCOMES AND QUALITY OF LIFE POST HEART TRANSPLANTATION. DATA TO BE COLLECTED WILL INCLUDE DEMOGRAPHIC DATA, PSYCHOSOCIAL DATA AND PHYSICAL DATA. TO DATE 552 PATIENTS HAVE COMPLETED THE SURVEY. STUDY TITLE: PROSPECTIVE, MULTI-CENTER, RANDOMIZED CLINICAL INVESTIGATION OF TRANSMEDICS ORGAN CARE SYSTEM (OCS) FOR CARDIAC USE SPONSOR: TRANSMEDICS PROJECT SUMMARY: THE TRANSMEDICS ORGAN CARE SYSTEM IS A PORTABLE ORGAN PERFUSION AND MONITORING SYSTEM INTENDED TO PRESERVE A DONATED HEART IN A BEATING STATE DURING TRANSPORT FOR THE EVENTUAL TRANSPLANTATION INTO A RECIPIENT. THE ORGAN CARE SYSTEM (OCS) MAINTAINS ORGAN VIABILITY BY PROVIDING A CONTROLLED ENVIRONMENT, CONTINUOUSLY PERFUSING THE DONATED HEART WITH WARM, OXYGENATED BLOOD, SUPPLEMENTED WITH THE TRANSMEDICS CARDIAC SOLUTION SET. THE BLOOD IS COLLECTED FROM THE DONOR AND IS CONTINUOUSLY CIRCULATED TO THE ORGAN IN A CLOSED CIRCUIT ALONG WITH THE CARDIAC SOLUTION SET. THE OCS PRESERVES THE HEART AND MONITORS THE ORGAN'S PERFUSION PARAMETERS IMMEDIATELY AFTER EXPLANTATION FROM A DONOR AND CONNECTION TO THE DEVICE, DURING TRANSPORTATION TO THE RECIPIENT SITE, AND UNTIL DISCONNECTION FROM THE DEVICE. THE PURPOSE OF THIS STUDY IS TO COMPARE THE SAFETY AND EFFECTIVENESS OF THE OCS WITH THE EXISTING COLD STATIC CARDIOPLEGIA STANDARD OF CARE FOR THE PRESERVATION OF DONOR HEARTS. CSMC ENROLLED 39 SUBJECTS IN THIS STUDY, WITH ALL FOLLOW-UP COMPLETE. STUDY TITLE: THE MEDICAL ARM OF MECHANICAL CIRCULATORY SUPPORT (MEDAMACS) STUDY SPONSOR: NIH/UNIVERSITY OF ALABAMA PROJECT SUMMARY: DESPITE WIDESPREAD USE OF EVIDENCE-BASED MEDICAL THERAPIES, MORTALITY AND MORBIDITY FROM SYSTOLIC HEART FAILURE REMAIN HIGH. BREAKTHROUGHS IN THE MECHANIC CIRCULATORY SUPPORT TECHNOLOGY HAVE EXTENDED SURVIVAL AND IMPROVED QUALITY IN ADVANCED HEART FAILURE PATIENTS AWAITING CARDIAC TRANSPLANTATION AND IN INOTROPE-DEPENDENT PATIENTS WHO ARE ELIGIBLE FOR HEART TRANSPLANT. THE INTERMACS REGISTRY HAS FACILITATED THE REFINEMENT OF PATIENT SELECTION FOR THIS THERAPY BY ANALYSIS OF THOSE PATIENTS WHO HAVE RECEIVED DEVICES. INTEGRAL TO THE ORIGINAL INTENT OF INTERMACS WAS COMPARISON TO AMBULATORY PATIENTS LIVING WITH ADVANCED HEART FAILURE WHO WERE NOT CURRENTLY RECEIVING MECHANICAL CIRCULATORY SUPPORT DEVICES. MEDAMACS WILL CHARACTERIZE THE TYPES OF PATIENTS WHO ARE NOT RECEIVING AN LVAD CURRENTLY DUE TO THE INTERSECTION OF RELATIVE CONTRAINDICATIONS, TO THEIR OWN PREFERENCES, OR TO THEIR CHARACTERIZATION AS "LESS SICK" EITHER BY PERCEPTION OR BY ABSOLUTE CRITERIA AS CURRENTLY DEFINED FOR LIFETIME VAD SUPPORT. THIS WILL BE A PROSPECTIVE, OBSERVATIONAL STUDY OF AMBULATORY PATIENTS WITH ADVANCED HEART FAILURE. STUDY ACTIVITIES INCLUDE BASELINE A (AT CONSENT), BASELINE B (3-6 WEEKS FOLLOWING CONSENT), 6 MONTH TELEPHONE CALL, 12 MONTH FOLLOW-UP, 18 MONTH TELEPHONE CALL, AND 24 MONTH FOLLOW-UP. RESEARCHERS WILL COLLECT DATA FROM 6 MINUTE WALK TESTS, MEDICAL RECORDS, AND QUESTIONNAIRES/SURVEYS. |
| FORM 990, PART III, LINE 4A | (CONTINUED) STUDY TITLE: THE DE-NOVO USE OF ECULIZUMAB ALONGSIDE CONVENTIONAL THERAPY THERAPY IN PRESENSITIZED PATIENTS RECEIVING CARDIAC TRANSPLANTATION: AN OPEN-LABEL, INVESTIGATOR-INITIATED PILOT TRIAL: [THE DUET CARDIAC TRIAL] SPONSOR: ALEXION PHARMACEUTICALS PROJECT SUMMARY: THE GROWING PROPORTION OF SENSITIZED CARDIAC RECIPIENTS PRESENTS AN ADDITIONAL CHALLENGE TO THE TRANSPLANT PRACTITIONER ATTEMPTING TO MINIMIZE THE OCCURRENCE OF ANTIBODY MEDIATED REJECTION (AMR). PATIENTS PRE-EXPOSED OR "SENSITIZED" TO ANTIGEN EXPOSING EVENTS (I.E.: BLOOD TRANSFUSIONS, MULTIPLE PREGNANCIES, PRIOR ORGAN TRANSPLANTATIONS, VENTRICULAR SUPPORT DEVICES) ARE MORE LIKELY TO BOTH POSSESS PREFORMED AND DEVELOP DE-NOVO ANTIBODIES. SENSITIZED PATIENTS WITH PANEL REACTIVE ANTIBODIES > 25% ARE AT RISK FOR INCREASED MORTALITY AFTER HEART TRANSPLANTATION. A CENTRAL COMPONENT OF ANTIBODY-MEDIATED CELL INJURY IS COMPLEMENT ACTIVATION. THE INHIBITION OF TERMINAL COMPLEMENT ACTIVATION MAY BE THE MISSING LINK TO DECREASING POSSIBLY BOTH COMPLEMENT-MEDIATED AMR AND CELLULAR REJECTION (CR) BY INHIBITING BOTH THE INFLAMMATORY EFFECTS OF BOTH CIRCULATING ANTIBODIES AND CYTOKINE INDUCED CELL DEATH. ECULIZUMAB IS A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO COMPLEMENT PROTEIN C5 WITH HIGH AFFINITY, THEREBY INHIBITING ITS CLEAVAGE TO C5A AND C5B AND PREVENTING THE GENERATION OF THE TERMINAL COMPLEMENT COMPLEX C5B-9. BY THIS MECHANISM, ECULIZUMAB (SOLIRIS) INHIBITS TERMINAL COMPLEMENT MEDIATED INTRAVASCULAR HEMOLYSIS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS. THIS STUDY IS A NON-RANDOMIZED, OPEN-LABEL, INVESTIGATOR-INITIATED SAFETY AND EFFICACY TRIAL INVESTIGATING THE DE-NOVO USE OF ECULIZUMAB ALONGSIDE CONVENTIONAL THERAPY TO PREVENT ANTIBODY MEDIATED REJECTION. THE DURATION OF THE STUDY WILL INCLUDE AN OPEN ENROLLMENT PERIOD AND AT LEAST 12 MONTHS OF FOLLOW-UP (POST-TRANSPLANT). THE TRIAL WILL ENROLL A TOTAL OF UP TO 10 "SENSITIZED" PATIENTS WITH A PANEL REACTIVE ANTIBODY SCORE OF GREATER THAN 70% AND NOT PREVIOUSLY OR CURRENTLY ENROLLED IN ANOTHER ONGOING TRIAL. AT THE TIME OF INITIAL BASELINE SCREENING PRIOR TO TRANSPLANTATION, PATIENTS WILLING TO CONSENT TO THE INVESTIGATIONAL USE OF ECULIZUMAB WILL BE ENROLLED IN THE TREATMENT ARM (COMPRISING A MAXIMUM OF 10 PATIENTS). THE USE OF ECULIZUMAB WILL BE UN-BLINDED TO ALL STUDY AND RESEARCH PRACTITIONER PARTICIPANTS. A HISTORICAL COHORT OF 10 ADDITIONAL PATIENTS WILL ALSO BE UTILIZED FOR COMPARISON. |
| FORM 990, PART VI, SECTION A, LINE 2 | LAURENCE MARTON, MD, DIRECTOR AND ERIC MARTON, PRESIDENT HAVE A FAMILY RELATIONSHIP. |
| FORM 990, PART VI, SECTION A, LINE 6 | CEDARS-SINAI MEDICAL CENTER IS THE SOLE CORPORATE MEMBER OF CALIFORNIA HEART CENTER FOUNDATION. |
| FORM 990, PART VI, SECTION A, LINE 7A | CEDARS-SINAI MEDICAL CENTER AS THE SOLE CORPORATE MEMBER, CAN ELECT BOARD OF DIRECTORS TO CALIFORNIA HEART CENTER FOUNDATION. |
| FORM 990, PART VI, SECTION A, LINE 7B | RESERVED RIGHTS OF CEDARS-SINAI MEDICAL CENTER, THE SOLE CORPORATE MEMBER OF THE ORGANIZATION. THE FOLLOWING ACTIONS MUST BE APPROVED OR ACTED UPON BY CEDARS-SINAI MEDICAL CENTER BEFORE BECOMING EFFECTIVE: (A) ANY SALE OR OTHER DISPOSITION OF ALL OR A SUBSTANTIAL PORTION OF THE ASSETS OF THE ORGANIZATION; (B) ANY MERGER OR AFFILIATION OF THE ORGANIZATION WITH ANY PERSON OR ENTITY OTHER THAN THE MEMBER; (C) ANY AMENDMENT TO THE ARTICLES OF INCORPORATION OR BYLAWS OF THE ORGANIZATION; (D) ANY ACT OR OMISSION WHICH CREATES ANY MATERIAL RISK TO THE MEMBER'S TAX EXEMPT STATUS, OR CREATES ANY MATERIAL RISK OF A VIOLATION OF ANY STATE OR FEDERAL LAWS; (E) DISSOLUTION OF THE ORGANIZATION OR THE FILING OF ANY BANKRUPTCY PETITION; (F) CREATION OF ANY NEW CORPORATION, PARTNERSHIP OR ASSOCIATION; (G) ACQUISITION OF OR THE INVESTMENT IN A NEW OPERATING BUSINESS; (H) ENTERING INTO ANY PARTNERSHIPS OR JOINT VENTURES; (I) ADOPTION OF OR CHANGES TO OPERATING OR CAPITAL BUDGETS; (J) ADOPTION OF THIS CORPORATION'S POLICIES AND PROCEDURES; (K) EXECUTION AND DELIVERY OF ANY NEW AFFILIATION AGREEMENTS AND OTHER RELATIONSHIPS WITH THE UCLA SCHOOL OF MEDICINE AND OTHER INSTITUTIONS OF MEDICAL LEARNING; (L) UNBUDGETED CAPITAL EXPENDITURES OVER $100,000; (M) LOANS, BORROWINGS OR GUARANTEES IN EXCESS OF $100,000, UNLESS APPROVED IN THE BUDGET; (N) ANY SECURITY INTERESTS OR MORTGAGES ON THE PROPERTY OF ORGANIZATION; (O) OPERATING OR CAPITAL LEASES WHERE THE TERM IS OVER FIVE YEARS OR THE TOTAL OBLIGATION UNDER THE LEASE EXCEEDS $100,000, UNLESS APPROVED IN THE BUDGET; (P) TERMINATION OR SELECTION OF THE AUDITORS OF THE ORGANIZATION; (Q) SUBJECT TO SECTION 5.08, APPOINTMENT OR REMOVAL OF ANY MEMBER OF THE BOARD (OTHER THAN EX-OFFICIO DIRECTORS); (R) APPOINTMENT OF REMOVAL OF ANY OFFICERS; (S) EXECUTION AND DELIVERY OF ANY PROFESSIONAL SERVICE AGREEMENTS; (T) RELOCATION OF PRINCIPAL OFFICE; (U) FIXING THE NUMBER OF DIRECTORS OF THE ORGANIZATION |
| FORM 990, PART VI, SECTION B, LINE 11 | THE ORGANIZATION'S FORM 990 UNDERGOES AN INTENSE AND HIGHLY COMPREHENSIVE REVIEW PROCESS. THE REVIEW INVOLVES VARIOUS MANAGEMENT PERSONNEL AND A BIG FOUR ACCOUNTING FIRM. |
| FORM 990, PART VI, SECTION B, LINE 12C | CONFLICT OF INTEREST POLICY ANNUAL STATEMENTS: EACH DIRECTOR, OFFICER, MEMBER OF A COMMITTEE WITH BOARD-DELEGATED POWERS AND ANY OTHER INTERESTED PERSON AS DETERMINED BY THE BOARD OR COMMITTEE SHALL AT LEAST ANNUALLY SIGN A COPY OF THE "STATEMENT PERTAINING TO CONFLICT OF INTEREST." IF A DIRECTOR, OFFICER, OR COMMITTEE MEMBER, OR DESIGNATED INTERESTED PERSON BECOMES AWARE THAT A POTENTIAL OR APPARENT CONFLICT MAY EXIST WHICH IS NOT DISCLOSED ON SUCH A STATEMENT, IT SHALL BE THE RESPONSIBILITY OF THE INTERESTED PERSON TO DISCLOSE THE POTENTIAL CONFLICT TO THE PRESIDENT AND TO THE BOARD OR APPROPRIATE COMMITTEE AND AS SET FORTH ABOVE, PRIOR TO ANY BOARD OR COMMITTEE DISCUSSIONS OR ACTION WITH RESPECT TO THE RELEVANT TRANSACTION OR ARRANGEMENT, AND, IF RELEVANT, TO LEAVE THE MEETING DURING THE DISCUSSION AND VOTE ON THE TRANSACTION OR ARRANGEMENT. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS: IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE RELEVANT CALIFORNIA HEART CENTER FOUNDATION ("CHCF") OFFICER OR ADMINISTRATOR SHALL DETERMINE WHETHER A CONFLICT OF INTEREST EXISTS. IF IT IS DETERMINED THAT A CONFLICT OF INTEREST EXISTS AND, NOTWITHSTANDING THE CONFLICT, THE CHCF OFFICER OR ADMINISTRATOR DETERMINES THAT IT CONTINUES TO BE IN THE BEST INTERESTS OF CHCF TO PROCEED WITH THE TRANSACTION OR ARRANGEMENT AT ISSUE, THE CHCF OFFICER OR ADMINISTRATOR SHALL REFER THE TRANSACTION OR ARRANGEMENT TO THE BOARD OR THE APPROPRIATE BOARD-DESIGNATED COMMITTEE FOR EVALUATION. ALTERNATIVELY IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF THE AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR COMMITTEE MEETING WHILE THE DETERMINATION OF THE EXISTENCE OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD OR COMMITTEE MEMBERS SHALL DECIDE, BY MAJORITY VOTE, IF A CONFLICT OF INTEREST EXISTS. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST: A. AN INTERESTED PERSON MAY MAKE A PRESENTATION TO THE BOARD OR COMMITTEE REGARDING THE TRANSACTION OR ARRANGEMENT. AFTER SUCH PRESENTATION THE INTERESTED PERSON MUST LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON THE TRANSACTION OR ARRANGEMENT. B. THE CHAIR OF THE BOARD OR COMMITTEE SHALL, IF DEEMED APPROPRIATE BY THE BOARD OR COMMITTEE, APPOINT A DISINTERESTED PERSON OR COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. C. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR COMMITTEE SHALL DETERMINE WHETHER CHCF CAN OBTAIN A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. D. IF A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE OF THE DISINTERESTED DIRECTORS WHETHER THE TRANSACTION OR ARRANGEMENT IS IN CHCF' BEST INTEREST AND FOR ITS OWN BENEFIT AND WHETHER THE TRANSACTION IS FAIR AND REASONABLE TO CHCF AND SHALL MAKE ITS DECISION AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT IN CONFORMITY WITH SUCH DETERMINATION. VIOLATIONS OF THE CONFLICTS POLICY: A. IF THE BOARD OR COMMITTEE HAS REASONABLE CAUSE TO BELIEVE THAT A MEMBER OF THE BOARD OR COMMITTEE OR AN OFFICER OR OTHER INTERESTED PERSON HAS FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL INFORM THE MEMBER OR OFFICER OR INTERESTED PERSON OF THE BASIS FOR SUCH BELIEF AND AFFORD SUCH PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. B. IF, AFTER HEARING THE RESPONSE OF SUCH PERSON AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE BOARD OR COMMITTEE DETERMINES THAT SUCH PERSON HAS IN FACT FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION. |
| FORM 990, PART VI, SECTION B, LINE 15B | THE EXECUTIVE PERSONNEL COMMITTEE (THE COMMITTEE) OF THE TAX-EXEMPT PARENT OF THE ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, IS A STANDING COMMITTEE OF THE BOARD OF DIRECTORS. THE COMMITTEE ADDRESSES COMPENSATION AND BENEFITS REGARDING THE ORGANIZATION'S CHIEF FINANCIAL OFFICER AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER, AND IS AUTHORIZED BY THE BOARD OF DIRECTORS TO ACT ON BEHALF OF THE BOARD WITH RESPECT TO SUCH ISSUES, AND OTHER GOVERNANCE ISSUES AS REQUESTED BY THE BOARD OF DIRECTORS, THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, THE CHAIR OF THE BOARD OF DIRECTORS, OR THE CEO, ALL SUBJECT TO THE COMMITTEE'S ONGOING REPORTING OBLIGATION TO THE BOARD OF DIRECTORS OR THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS. SPECIFICALLY, THE COMMITTEE EVALUATES THE PERFORMANCE AND APPROVES THE COMPENSATION AND BENEFITS FOR THE ORGANIZATION'S CHIEF FINANCIAL OFFICER AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER. THE MEMBERS OF THE COMMITTEE ARE APPOINTED ANNUALLY BY THE CHAIR OF THE MEDICAL CENTER'S BOARD OF DIRECTORS. APPOINTMENTS ARE FOR A ONE YEAR TERM. EACH YEAR, THE COMMITTEE FOLLOWS A PROCESS THAT ENSURES THAT THE COMPENSATION AND BENEFITS IS REASONABLE AND IN COMPLIANCE WITH APPLICABLE LAWS AND REGULATIONS. THE MEDICAL CENTER'S SVP OF HR PROVIDES STAFF SUPPORT TO THE COMMITTEE. THE COMMITTEE MAY INCLUDE MEMBERS OF THE MEDICAL CENTER'S MANAGEMENT TEAM OR ANY OTHER PERSON WHOSE PRESENCE THE COMMITTEE BELIEVES TO BE DESIRABLE OR APPROPRIATE. THE COMMITTEE MAY ENGAGE AN INDEPENDENT COMPENSATION AND BENEFITS CONSULTANT AND ANY OTHER ADVISORS THEY DEEM NECESSARY. THE COMMITTEE MAY ALSO ENGAGE INDEPENDENT COUNSEL. THE MEDICAL CENTER WILL PROVIDE FOR APPROPRIATE FUNDING FOR PAYMENT OF COSTS TO ANY SUCH PERSONS RETAINED BY THE COMMITTEE. ANNUALLY, AT THE COMMITTEE'S DIRECTION, THE INDEPENDENT COMPENSATION CONSULTANT SHALL PREPARE SUCH REPORTS AS THE COMMITTEE REASONABLY DEEMS NECESSARY. AT A MINIMUM, SUCH REPORTS WILL INCLUDE MARKET SURVEY DATA FROM A PEER GROUP DESIGNATED BY THE COMMITTEE, WHICH SHALL BE CONSIDERED BY THE COMMITTEE PRIOR TO MAKING DECISIONS. THE COMMITTEE MEETS AS FREQUENTLY AS THE COMMITTEE DEEMS NECESSARY AND WILL MAINTAIN WRITTEN MINUTES OF ITS MEETING. THE COMPENSATION AND BENEFITS OF THE PRESIDENT AND VICE-PRESIDENT ARE DETERMINED BY THE CHIEF FINANCIAL OFFICER OF THE ORGANIZATION WITH ASSISTANCE FROM HR WHICH PROVIDES AN INDEPENDENT REVIEW OF COMPARABLES. |
| FORM 990, PART VI, SECTION C, LINE 19 | THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, ITS CONFLICT OF INTEREST POLICY AND ITS TAX-EXEMPT PARENT'S AUDITED FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON WRITTEN REQUEST. |
Schedule R IRS990ScheduleR
Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (3 entries)
| Address Line1USAddress/AddressLine1 | CityUSAddress/City | StateUSAddress/State | ZIP CodeUSAddress/ZIPCode | EINEIN | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile StateLegalDomicileStateCd | Exempt Code SectionExemptCodeSectionTxt | Public Charity StatusPublicCharityStatusTxt | Direct Controlling NADirectControllingNACd | Controlled OrganizationControlledOrganizationInd | Business Name Line1DirectControllingEntityName/BusinessNameLine1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CEDARS-SINAI MEDICAL CENTER | |||||||||||
| 8700 BEVERLY BOULEVARD | LOS ANGELES | CA | 90048 | 951644600 | HEALTHCARE | CA | 501(C)(3) | LINE 3 | N/A | 0 | |
| CEDARS-SINAI MEDICAL CARE FOUNDATION | |||||||||||
| 200 N ROBERTSON BOULEVARD 101 | BEVERLY HILLS | CA | 90211 | 954457756 | PROVISION OF MEDICAL CARE, TEACHING AND RESEARCH | CA | 501(C)(3) | LINE 11A, I | Yes (1) | CEDARS-SINAI MEDICAL CENTER | |
| (no name) | |||||||||||
| Yes (1) | |||||||||||
Id Related Org Txbl Corp Tr IdRelatedOrgTxblCorpTrGrp (2 entries)
| Address Line1USAddress/AddressLine1 | CityUSAddress/City | StateUSAddress/State | ZIP CodeUSAddress/ZIPCode | EINEIN | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile StateLegalDomicileStateCd | Direct Controlling NADirectControllingNACd | Entity TypeEntityTypeTxt | Controlled OrganizationControlledOrganizationInd |
|---|---|---|---|---|---|---|---|---|---|
| GRTR VALLEY MGMT SVCS ORG INC | |||||||||
| 6500 WILSHIRE BLVD 8TH FLR | LOS ANGELES | CA | 90048 | 954439758 | MANAGEMENT FUNCTIONS | CA | N/A | C | Yes (1) |
| OPTIMATRIX HEALTH SOLUTIONS INC | |||||||||
| 6500 WILSHIRE BLVD 9TH FLOOR | LOS ANGELES | CA | 90048 | 954522779 | INFORMATION SYSTEMS | CA | N/A | C | Yes (1) |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Receipt Of Int Annts Rnts Rylts | 0 | ReceiptOfIntAnntsRntsRyltsInd |
| Gift Grnt Or Cap Contri To Oth Org | 0 | GiftGrntOrCapContriToOthOrgInd |
| Gift Grnt Cap Contri From Oth Org | Yes (1) | GiftGrntCapContriFromOthOrgInd |
| Loans Or Guarantees To Other Org | 0 | LoansOrGuaranteesToOtherOrgInd |
| Loans Or Guarantees From Oth Org | 0 | LoansOrGuaranteesFromOthOrgInd |
| Div Related Organization | 0 | DivRelatedOrganizationInd |
| Asset Sale To Other Org | 0 | AssetSaleToOtherOrgInd |
| Asset Purchase From Other Org | 0 | AssetPurchaseFromOtherOrgInd |
| Asset Exchange | 0 | AssetExchangeInd |
| Rental Of Facilities To Oth Org | 0 | RentalOfFacilitiesToOthOrgInd |
| Rental Of Fclts From Oth Org | 0 | RentalOfFcltsFromOthOrgInd |
| Perform Of Services For Oth Org | 0 | PerformOfServicesForOthOrgInd |
| Perform Of Services By Other Org | 0 | PerformOfServicesByOtherOrgInd |
| Sharing Of Facilities | 0 | SharingOfFacilitiesInd |
| Paid Employees Sharing | Yes (1) | PaidEmployeesSharingInd |
| Reimbursement Paid To Other Org | Yes (1) | ReimbursementPaidToOtherOrgInd |
| Reimbursement Paid By Other Org | 0 | ReimbursementPaidByOtherOrgInd |
| Transfer To Other Org | 0 | TransferToOtherOrgInd |
| Transfer From Other Org | 0 | TransferFromOtherOrgInd |
Comments